Regeneron Pharmaceuticals reported revenue of $4290.70M and net income of $1296.90M for the quarter ended Jun 2026, up 16.7% year over year. This income statement covers 69 quarters of results from Jun 2009 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2009 | Sep2009 | Dec2009 | Mar2010 | Jun2010 | Sep2010 | Dec2010 | Mar2011 | Jun2011 | Sep2011 | Dec2011 | Mar2012 | Jun2012 | Sep2012 | Dec2012 | Mar2013 | Jun2013 | Sep2013 | Dec2013 | Mar2014 | Jun2014 | Sep2014 | Dec2014 | Mar2015 | Jun2015 | Sep2015 | Dec2015 | Mar2016 | Jun2016 | Sep2016 | Dec2016 | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue | 3,452.80M | 4,951.70M | 2,965.10M | 2,857.20M | 2,936.20M | 100.00M | 3,162.10M | 3,158.10M | 3,362.70M | 3,434.30M | 3,145.00M | 3,547.10M | 3,720.70M | 3,789.20M | 3,028.70M | 3,675.60M | 3,754.30M | 3,884.30M | 3,605.40M | 4,290.70M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Cost of RevenueCost of Rev | 238.80M | 811.70M | 207.30M | 149.20M | 176.50M | 278.00M | 249.10M | 212.50M | 224.50M | 258.60M | 240.40M | 257.80M | 262.30M | 326.80M | 265.50M | 275.60M | 281.00M | 318.70M | 373.40M | 360.70M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Gross Profit | 3,214.00M | 4,140.00M | 2,757.80M | 2,708.00M | 2,759.70M | -178.00M | 2,913.00M | 2,945.60M | 3,138.20M | 3,175.70M | 2,904.60M | 3,289.30M | 3,458.40M | 3,462.40M | 2,763.20M | 3,400.00M | 3,473.30M | 3,565.60M | 3,232.00M | 3,930.00M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 665.40M | 737.60M | 843.80M | 794.30M | 911.30M | 1,043.10M | 1,101.20M | 1,085.30M | 1,075.30M | 1,177.20M | 1,248.40M | 1,200.00M | 1,271.50M | 1,412.10M | 1,327.40M | 1,421.70M | 1,475.00M | 1,626.10M | 1,543.50M | 1,631.60M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Selling, General & AdministrativeSG&A | 445.00M | 559.60M | 450.00M | 476.30M | 529.10M | 660.50M | 601.10M | 652.00M | 640.50M | 737.70M | 689.00M | 758.80M | 714.40M | 792.20M | 633.00M | 634.20M | 657.80M | 775.00M | 647.70M | 662.10M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | -42.00M | 15.80M | 20.20M | 17.40M | 45.70M | 6.60M | 0.50M | 0.60M | 0.50M | 0.50M | -15.30M | -14.60M | -8.00M | -15.50M | 10.00M | 771.30M | 703.50M | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Operating ExpensesOpex | 1,605.60M | 2,312.00M | 1,706.60M | 1,747.30M | 1,712.50M | 2,267.60M | 2,215.40M | 2,141.60M | 2,251.70M | 2,461.40M | 2,393.60M | 2,477.50M | 2,541.20M | 2,799.00M | 2,437.00M | 2,596.10M | 2,727.50M | 3,004.40M | 2,962.50M | 2,997.20M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Operating IncomeOp. Inc | 1,847.20M | 2,639.70M | 1,258.50M | 1,109.90M | 1,223.70M | 1,146.80M | 946.70M | 1,016.50M | 1,111.00M | 972.90M | 751.40M | 1,069.60M | 1,179.50M | 990.20M | 591.70M | 1,079.50M | 1,026.80M | 879.90M | 642.90M | 1,293.50M | |||||||||||||||||||||||||||||||||||||||||||||||||
| EBIT | 1,847.20M | 2,639.70M | 1,258.50M | 1,109.90M | 1,223.70M | 1,146.80M | 946.70M | 1,016.50M | 1,111.00M | 972.90M | 751.40M | 1,069.60M | 1,179.50M | 990.20M | 591.70M | 1,079.50M | 1,026.80M | 879.90M | 642.90M | 1,293.50M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Non-operating items | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 14.20M | 14.10M | 13.60M | 13.10M | 15.30M | 17.40M | 18.00M | 18.90M | 17.80M | 18.30M | 16.10M | 14.80M | 13.80M | 10.50M | 8.70M | 3.60M | 19.30M | 12.20M | 12.90M | 11.00M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | -6.40M | -35.90M | -144.90M | -53.70M | -51.30M | 36.30M | 57.20M | -15.70M | 21.30M | 95.40M | 3.50M | 7.90M | 128.20M | -66.00M | 38.10M | 22.10M | 15.70M | 7.10M | -65.80M | -48.00M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -16.40M | -122.20M | -183.80M | -133.60M | 301.40M | 195.30M | -70.70M | 85.30M | 17.60M | 193.00M | -34.60M | 573.30M | 327.30M | -21.60M | 322.00M | 442.80M | 755.80M | 176.00M | 201.20M | 245.30M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -30.60M | -136.30M | -197.40M | -146.70M | 286.10M | 177.90M | -88.70M | 66.40M | -0.20M | 174.70M | -50.70M | 558.50M | 313.50M | -32.10M | 313.30M | 439.20M | 736.50M | 163.80M | 188.30M | 234.30M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EBT | 1,816.60M | 2,503.40M | 1,061.10M | 963.20M | 1,509.80M | 1,324.70M | 858.00M | 1,082.90M | 1,110.80M | 1,147.60M | 700.70M | 1,628.10M | 1,493.00M | 958.10M | 905.00M | 1,518.70M | 1,763.30M | 1,043.70M | 831.20M | 1,527.80M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tax ProvisionsTaxes | 184.40M | 274.40M | 87.60M | 111.10M | 194.10M | 127.60M | 40.20M | 114.50M | 103.00M | -12.00M | -21.30M | 195.80M | 152.40M | 40.40M | 96.30M | 127.10M | 303.30M | 199.10M | 104.00M | 230.90M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Profit After TaxPAT | 1,632.20M | 2,229.00M | 973.50M | 852.10M | 1,315.70M | 1,197.10M | 817.80M | 968.40M | 1,028.70M | 1,255.50M | 722.00M | 1,432.30M | 1,470.70M | 849.60M | 808.70M | 1,415.00M | 1,476.50M | 853.10M | 727.20M | 1,296.90M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income from Non-Controlling InterestsInc. Minority | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | 1,632.20M | 2,229.00M | 973.50M | 852.10M | 1,315.70M | 1,197.10M | 817.80M | 968.40M | 1,007.80M | 1,159.60M | 722.00M | 1,432.30M | 1,340.60M | 917.70M | 808.70M | 1,391.60M | 1,460.00M | 844.60M | 727.20M | 1,296.90M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | 1,632.20M | 2,229.00M | 973.50M | 852.10M | 1,315.70M | 1,197.10M | 817.80M | 968.40M | 1,007.80M | 1,159.60M | 722.00M | 1,432.30M | 1,340.60M | 917.70M | 808.70M | 1,391.60M | 1,460.00M | 844.60M | 727.20M | 1,296.90M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income towards Parent CompanyParent Net Inc | 1,632.20M | 2,229.00M | 973.50M | 852.10M | 1,315.70M | 1,197.10M | 817.80M | 968.40M | 1,007.80M | 1,159.60M | 722.00M | 1,432.30M | 1,340.60M | 917.70M | 808.70M | 1,391.60M | 1,460.00M | 844.60M | 727.20M | 1,296.90M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | 1,632.20M | 2,229.00M | 973.50M | 852.10M | 1,315.70M | 1,197.10M | 817.80M | 968.40M | 1,007.80M | 1,159.60M | 722.00M | 1,432.30M | 1,340.60M | 917.70M | 808.70M | 1,391.60M | 1,460.00M | 844.60M | 727.20M | 1,296.90M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Additional items | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS (Basic) | 15.37 | 21.09 | 9.12 | 7.90 | 12.31 | 11.18 | 7.64 | 9.05 | 9.48 | 10.87 | 6.70 | 13.25 | 12.40 | 8.51 | 7.58 | 13.24 | 14.09 | 8.07 | 6.99 | 12.62 | |||||||||||||||||||||||||||||||||||||||||||||||||
| EPS (Diluted) | 14.33 | 19.87 | 8.61 | 7.47 | 11.66 | 10.55 | 7.17 | 8.50 | 8.89 | 10.20 | 6.27 | 12.41 | 11.54 | 7.97 | 7.27 | 12.81 | 13.62 | 7.78 | 6.75 | 12.23 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares Outstanding | 106.20M | 105.70M | 106.80M | 107.90M | 106.90M | 107.10M | 107.10M | 107.00M | 106.30M | 106.70M | 107.80M | 108.10M | 108.10M | 107.90M | 106.70M | 105.10M | 103.60M | 104.60M | 104.00M | 102.80M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 113.90M | 112.20M | 113.10M | 114.00M | 112.80M | 113.50M | 114.00M | 113.90M | 113.40M | 113.70M | 115.10M | 115.40M | 116.20M | 115.10M | 111.20M | 108.60M | 107.20M | 108.60M | 107.70M | 106.00M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 124.60M | 126.20M | 127.60M | 128.30M | 106.90M | 107.10M | 107.10M | 107.00M | 106.30M | 106.70M | 107.80M | 108.10M | 108.10M | 107.90M | 106.70M | 105.10M | 103.60M | 104.60M | 104.00M | 102.80M | |||||||||||||||||||||||||||||||||||||||||||||||||
| EBITDA | 1,847.20M | 2,639.70M | 1,258.50M | 1,109.90M | 1,223.70M | 1,146.80M | 946.70M | 1,016.50M | 1,111.00M | 972.90M | 751.40M | 1,069.60M | 1,179.50M | 990.20M | 591.70M | 1,079.50M | 1,026.80M | 879.90M | 642.90M | 1,293.50M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Interest ExpensesInt Expense | 14.20M | 14.10M | 13.60M | 13.10M | 15.30M | 17.40M | 18.00M | 18.90M | 17.80M | 18.30M | 16.10M | 14.80M | 13.80M | 10.50M | 8.70M | 3.60M | 19.30M | 12.20M | 12.90M | 11.00M | |||||||||||||||||||||||||||||||||||||||||||||||||
| Tax Rate | 10.15% | 10.96% | 8.26% | 11.53% | 12.86% | 9.63% | 4.69% | 10.57% | 9.27% | -1.05% | -3.04% | 12.03% | 10.21% | 4.22% | 10.64% | 8.37% | 17.20% | 19.08% | 12.51% | 15.11% |